Asthma - Pipeline Insight, 2026

This “Asthma - Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Asthma: Understanding

Asthma: Overview

Asthma is a prevalent chronic inflammatory respiratory condition affecting millions of people worldwide and presents substantial challenges in both diagnosis and management. This respiratory condition is characterized by inflammation of the airways, causing intermittent airflow obstruction and bronchial hyperresponsiveness. The prevalence and severity of asthma are determined by a complex interplay between genetic and environmental factors.

Asthma symptoms vary between individuals and can sometimes worsen into episodes known as asthma attacks, often occurring at night or during physical activity. Common signs include a persistent cough (especially at night), wheezing during breathing, shortness of breath even at rest, and a feeling of chest tightness that makes deep breathing difficult. Symptoms may intensify with triggers such as colds, weather changes, dust, smoke, pollen, or strong odors. Since similar symptoms can arise from other conditions, it is important to consult a healthcare provider for proper evaluation and diagnosis.

Asthma is a syndrome characterized by diverse underlying mechanisms and involves intricate interactions among inflammatory and resident airway cells. These mechanisms lead to airway inflammation, intermittent airflow obstruction, and bronchial hyperresponsiveness. It is often driven by a Th2-mediated immune response, where cytokines promote IgE production and eosinophilic inflammation after allergen exposure. IgE-bound mast cells release mediators like histamine and leukotrienes, causing rapid bronchoconstriction followed by a delayed inflammatory response. Airflow limitation results from smooth muscle contraction, airway wall edema, mucus plugging, and structural changes. Persistent inflammation can lead to airway remodeling, including fibrosis and epithelial damage, which may cause irreversible lung function decline. Dysregulated mediator pathways, such as increased leukotrienes, further enhance bronchoconstriction.

Asthma is a multifactorial condition arising from complex interactions between genetic predisposition and environmental exposures. Genetic factors influence susceptibility, with several genes linked to immune regulation, inflammation, and airway responsiveness, while environmental triggers determine whether these genetic risks manifest. A major risk factor is atopy, a tendency to develop IgE-mediated allergic responses to common allergens. Early-life influences such as prematurity, maternal smoking, poor maternal nutrition, and viral respiratory infections can impair lung development and increase long-term risk.

Asthma diagnosis is based on characteristic intermittent symptoms and confirmation of variable airflow limitation, typically using spirometry showing an obstructive pattern with reduced FEV1/FVC ratio and reversibility after bronchodilator use. Additional tests such as bronchoprovocation, peak flow monitoring, and exhaled nitric oxide can support diagnosis, especially in atypical cases. Imaging and laboratory tests help exclude alternative conditions or assess complications. Management focuses on patient education, trigger avoidance, and proper inhaler technique, often guided by a personalized asthma action plan. Treatment follows a stepwise approach based on symptom severity, starting with rapid-acting bronchodilators and progressing to inhaled corticosteroids and combination therapies. Severe or uncontrolled cases may require add-on treatments such as long-acting bronchodilators, anticholinergics, or biologic agents targeting specific inflammatory pathways.

"Asthma - Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Asthma pipeline landscape is provided which includes the disease overview and Asthma treatment guidelines. The assessment part of the report embraces, in depth Asthma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The therapies under development are focused on novel approaches to treat/improve Asthma.

Asthma Emerging Drugs Chapters

This segment of the Asthma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Asthma Emerging Drugs

• GB-0895: Generate:Biomedicines

GB-0895 is an investigational antibody that binds and neutralizes thymic stromal lymphopoietin (TSLP) to help reduce downstream inflammatory signaling in severe asthma. Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that helps drive airway inflammation and asthma exacerbations. It is engineered for an extended half-life and is being studied for twice-yearly subcutaneous dosing, which may offer administration flexibility and convenience if proven safe and effective. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Asthma.

• AZD-4604: AstraZeneca

AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care. Due to the broad anti-inflammatory properties of JAK1 inhibition, AZD4604 is predicted to provide benefit to steroid sensitive and insensitive asthma endotypes, thereby offering a differentiation opportunity from existing biologics. In a preclinical ovalbumin-challenge rat model of allergic asthma, lung and systemic delivered AZD4604 showed reduction of pSTAT3 and pSTAT5, indicating target engagement in the lung. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Asthma.

• ENV-294: Enveda

ENV-294 is a novel, first-in-class, small molecule discovered using Enveda's proprietary platform for the treatment of multiple inflammatory conditions. It targets a novel non-kinase inflammatory pathway distinct from current advanced therapies like JAK-STAT or cytokine signaling, aiming to deliver an oral agent with high efficacy and favorable safety. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Asthma.

• CDX-622: Celldex Therapeutics

CDX-622 is a bispecific antibody that targets two complementary, clinically validated pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. SCF activation of the KIT receptor is required for mast cell survival and plays a key role in their activation, maturation and tissue recruitment. Combined neutralization of SCF and TSLP with CDX-622 is expected to simultaneously reduce tissue mast cells and inhibit Type 2 inflammatory responses to potentially offer enhanced therapeutic benefit in inflammatory and fibrotic disorders. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Asthma.

• SM17: SinoMab BioScience Ltd

SM17 is a novel, first-in-class humanized IgG4-κ monoclonal anƟbody designed to modulate Type II inflammatory responses by targeƟng the receptor of interleukin 25 (IL-25), an “alarmin” molecule central to Type 2 immunity. By binding to the IL-25 receptor (IL-17RB) on Type 2 innate lymphoid cells (ILC2s) and Th2 cells, SM17 blocks IL-25-induced signaling cascades and suppresses downstream cytokines including IL-4, IL-5, and IL-13. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Asthma.

Asthma: Therapeutic Assessment

This segment of the report provides insights about the different Asthma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Asthma

• There are approx. 80+ key companies which are developing the therapies for Asthma. The companies which have their Asthma drug candidates in the most advanced stage, i.e. Phase III include, Generate:Biomedicines.

Phases

The report covers around 100+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Asthma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Asthma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Asthma drugs.

Asthma Report Insights

• Asthma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Asthma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Asthma drugs?
• How many Asthma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Asthma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Asthma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Asthma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Generate:Biomedicines
• AstraZeneca
• Enveda
• Celldex Therapeutics
• SinoMab BioScience Ltd
• Anhui Palo Alto Pharmaceuticals, Inc.
• HUNAN MABGEEK BIOTECH CO., LTD
• Chiesi Farmaceutici S.p.A.
• Arrowhead Pharmaceuticals
• Akeso
• Keymed Biosciences Co.Ltd
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Pfizer
• Ethris GmbH
• Windward Bio
• Upstream Bio Inc.
• Jemincare
• Longbio Pharma
• Kymera Therapeutics, Inc.
• Avalo Therapeutics, Inc.
• Haisco Pharmaceutical Group Co., Ltd.
• Innovent Biologics (Suzhou) Co. Ltd.
• Sanofi
• Amgen
• Adovate, LLC

Key Products

• GB-0895
• AZD-4604
• ENV-294
• CDX-622
• SM17
• PA9159
• MG-ZG122
• CHF-6001
• ARO-RAGE
• AK139
• CM512
• SHR-4597
• PF-07275315
• ETH-47
• WIN-378
• Verekitug
• JYB-1904
• LP-003
• KT-621
• AVTX-002
• HSK-31858
• IBI3002
• SAR-443765
• AMG691
• ADO-5030

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 5-7 business days.